Pharmaceutical compositions of anisomelic acid and the use thereof

Abstract

A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided.

Description

technical field

[0001] The present invention relates to a new application of a compound Anisomelic acid (AA), which is isolated from Anisomeles malabarica. In particular, the present invention relates to the pharmaceutical composition of parsnip oxalic acid. The invention also discloses the use of the parsnip oxalic acid and its composition in antiviral cancer treatment. Background technique

[0002] Cervical cancer is the second most common malignancy affecting women worldwide, with approximately 500,000 new cases diagnosed each year, and 280,000 deaths. Although surgery and chemo-radiation therapy cure 80-95% of women with early stage cancer and 60% and 60% of locally advanced cancer, disease recurrence and metastasis remain the leading causes of cancer death. Current options for cytotoxic treatment of advanced and metastatic cancers show mediocre results, with response rates of maximal 30% and overall survival numbers of less than 10 months. With the limited success of...

Images